Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + lamivudine versus efavirenz + lamivudine + tenofovir disoproxil fumarate in treatment-naive HIV infection
ChiCTR2300072308Phase 4Completed
- Sponsor
- Chest Hospital of Guangxi Zhuang Autonomous Region
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dolutegravir, lamivudine, efavirenz and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Chest Hospital of Guangxi Zhuang Autonomous Region. Primary endpoints: HIV viral load, CD4+ T-lymphocyte count and 1 more. Started Jun 2023; status: completed.
02
Drugs
dolutegravirlamivudineefavirenztenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2300072308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072308.